ELDN

Eledon Pharmaceuticals, Inc. (ELDN) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing tegoprubart, an anti-CD40L antibody, for the prevention of organ transplant rejection (kidney, xenotransplantation, islet cell) and the treatment of amyotrophic lateral sclerosis (ALS). The company has no approved products and generates no product revenue.

Key Financial Metrics

Note: Q1 2025 comparative figures for cash and working capital are derived from the balance sheet roll-forward and prior period data where explicitly stated or calculable.

Material Changes vs. Prior Period

• Net Loss Expansion: Net loss increased significantly to $39.0 million from $6.5 million in Q1 2025. This was primarily driven by a $19.0 million non-cash loss due to the change in fair value of warrant liabilities, reflecting an increase in the company's stock price during the quarter.
• Operating Expenses: Total operating expenses rose to $21.2 million (up $3.2 million).
  • R&D Expenses: Increased to $17.2 million, driven by a $6.1 million rise in manufacturing costs for clinical trial supply, partially offset by a $3.1 million decrease in kidney transplantation program costs due to Phase 2 trial close-out activities.
  • G&A Expenses: Decreased to $4.0 million, primarily due to a $0.7 million reduction in stock-based compensation as prior awards vested.
• Liquidity: Cash and cash equivalents decreased from $22.8 million to $6.2 million, while short-term investments decreased from $110.5 million to $104.9 million. Total cash burn from operating activities was $22.6 million.

Guidance, Outlook, and Risks

• Clinical Progress:
  • Kidney Transplant: The Phase 2 BESTOW trial dosing was completed in September 2025. Topline data (announced Nov 2025) showed tegoprubart maintained strong renal function (eGFR ~69 vs 66 for tacrolimus) with a superior safety profile (lower rates of new-onset diabetes, tremor, and cardiovascular events). The company plans to seek FDA guidance for a Phase 3 trial in 2026.
  • ALS: The company is seeking to progress clinical development but explicitly states it cannot continue this program without additional financing.
  • Islet Cell Transplant: An investigator-initiated trial at the University of Chicago showed promising results with 100% insulin independence in patients with follow-up data.
• Liquidity Outlook: Management estimates current resources ($111.1 million) are sufficient to fund operations for at least the next 12 months. However, initiating a Phase 3 kidney trial or a company-sponsored islet cell study will require substantial additional capital.
• Risks:
  • Capital Requirements: Failure to raise additional capital could force the company to curtail operations or liquidate.
  • Warrant Liability Volatility: The fair value of warrant liabilities is sensitive to stock price fluctuations, causing significant volatility in reported net loss.
  • Regulatory & Clinical Risk: No assurance that Phase 3 trials will be successful or that regulatory approval will be obtained.

Investor Verification Checklist

• Verify the cash runway assumptions, specifically the cost estimates for the planned Phase 3 kidney transplantation trial.
• Review the Phase 2 BESTOW trial data details regarding the non-inferiority margin and the specific safety advantages over tacrolimus to assess Phase 3 viability.
• Monitor the fair value of warrant liabilities and its impact on quarterly net loss, as this is a non-cash item driven by stock price volatility.
• Assess the status of the ALS program funding, as the filing explicitly states development will halt without new capital.
• Check for updates on the 2024 Equity Distribution Agreement (ATM program), which had $0 sales as of March 31, 2026, but remains a potential funding source.